1. Market Research
  2. > Psychiatric Disorders - Pipeline Review, H2 2013

Psychiatric Disorders - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 83 pages

Psychiatric Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Psychiatric Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychiatric Disorders. Psychiatric Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Psychiatric Disorders.
- A review of the Psychiatric Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Psychiatric Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Psychiatric Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Psychiatric Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Psychiatric Disorders - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Psychiatric Disorders Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Psychiatric Disorders 10
Psychiatric Disorders Therapeutics under Development by Companies 12
Psychiatric Disorders Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Psychiatric Disorders Therapeutics - Products under Development by Companies 19
Psychiatric Disorders Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Psychiatric Disorders Therapeutics Development 21
Boehringer Ingelheim GmbH 21
Dainippon Sumitomo Pharma Co., Ltd. 22
Samyang Corporation 23
H Lundbeck A/S 24
AVANIR Pharmaceuticals 25
Corcept Therapeutics Incorporated 26
Suven Life Sciences Ltd. 27
Angelini Group 28
Snowdon Inc. 29
Critical Pharmaceuticals Limited 30
CoLucid Pharmaceuticals, Inc. 31
GP Pharm, S.A. 32
PsychoGenics, Inc. 33
Omeros Corporation 34
Edison Pharmaceuticals, Inc. 35
Psychiatric Disorders - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
tedatioxetine - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Selective Glucocorticoid Receptor-II Antagonists - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
risperidone - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
GSK-3 Beta Inhibitor - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Program For Neurological Disorders - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
CORT-113083 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
mifepristone - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
LuAF-11167 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
BI-409306 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
PRX-12251 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
NRG-101 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Conjugated Stigmine Program - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Drug Targeting GPR83 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
AVP-786 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Drug Targeting GPR162 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Compound-74 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Drug Targetting 5HTT/5HT2C - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Adenosine Antagonists - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
SEP-360 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
PBF-999 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Tetrahydronaphthalene Derivatives - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Aromatic Cyclopropanes - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
Homotropanes - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
Tropane Prodrugs - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Tetrahydropyridines - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Substituted Pyrrolidines - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
EPI-589 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
NSTR3 Derived Peptide - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
risperidone Fast Dissolving Tablet - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
risperidone Depot - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
UBP-618 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
Psychiatric Disorders Therapeutics - Drug Profile Updates 73
Psychiatric Disorders Therapeutics - Discontinued Products 75
Psychiatric Disorders Therapeutics - Dormant Products 76
Psychiatric Disorders - Product Development Milestones 77
Featured News and Press Releases 77
Jun 05, 2013: Avanir Pharma Announces Accelerated Development Path For AVP-786 Following Successful Pre-IND Meeting With FDA 77
Feb 07, 2013: Avanir Pharma Announces Positive Interim Data From Pharmacokinetic Study With AVP-786 77
Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors 78
Sep 01, 2011: FDA Reports Serious Allergic Reactions From Saphris Usage 78
May 02, 2011: Prexa Pharmaceuticals Hires Experienced Development Team to Advance Lead Product Candidate PRX-12251 78
Dec 16, 2010: Otsuka Announces Defendants Appeal From Final Judgment In US Abilify Patent Litigation 79
Nov 16, 2010: Otsuka Prevails In US Abilify Patent Litigation 79
Apr 23, 2010: Seroquel XR Recommended For Approval In EU as an Add-On Treatment Of Major Depressive Disorder 79
Apr 06, 2010: AVANIR To Present Zenvia Phase III Data At AAN Annual Meeting 79
Mar 29, 2010: Cellceutix Announces Positive Results From Animal Studies Of Autism Compound KM-391 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83



List of Tables

Number of Products Under Development for Psychiatric Disorders, H2 2013 10
Products under Development for Psychiatric Disorders - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
Boehringer Ingelheim GmbH, H2 2013 21
Dainippon Sumitomo Pharma Co., Ltd., H2 2013 22
Samyang Corporation, H2 2013 23
H Lundbeck A/S, H2 2013 24
AVANIR Pharmaceuticals, H2 2013 25
Corcept Therapeutics Incorporated, H2 2013 26
Suven Life Sciences Ltd., H2 2013 27
Angelini Group, H2 2013 28
Snowdon Inc., H2 2013 29
Critical Pharmaceuticals Limited, H2 2013 30
CoLucid Pharmaceuticals, Inc., H2 2013 31
GP Pharm, S.A., H2 2013 32
PsychoGenics, Inc., H2 2013 33
Omeros Corporation, H2 2013 34
Edison Pharmaceuticals, Inc., H2 2013 35
Assessment by Monotherapy Products, H2 2013 36
Assessment by Stage and Route of Administration, H2 2013 38
Assessment by Stage and Molecule Type, H2 2013 40
Psychiatric Disorders Therapeutics - Drug Profile Updates 73
Psychiatric Disorders Therapeutics - Discontinued Products 75
Psychiatric Disorders Therapeutics - Dormant Products 76



List of Figures

Number of Products under Development for Psychiatric Disorders, H2 2013 10
Products under Development for Psychiatric Disorders - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Discovery and Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 36
Assessment by Route of Administration, H2 2013 37
Assessment by Stage and Route of Administration, H2 2013 38
Assessment by Molecule Type, H2 2013 39
Assessment by Stage and Molecule Type, H2 2013 40



Companies Mentioned

Boehringer Ingelheim GmbH
Dainippon Sumitomo Pharma Co., Ltd.
Samyang Corporation
H Lundbeck A/S
AVANIR Pharmaceuticals
Corcept Therapeutics Incorporated
Suven Life Sciences Ltd.
Angelini Group
Snowdon Inc.
Critical Pharmaceuticals Limited
CoLucid Pharmaceuticals, Inc.
GP Pharm, S.A.
PsychoGenics, Inc.
Omeros Corporation
Edison Pharmaceuticals, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.